Otezla (Apremilast)

Apremilast selectively inhibits phosphodiesterase‑4 (PDE4), an enzyme that breaks down cyclic AMP. By raising intracellular cAMP levels, it down‑regulates pro‑inflammatory cytokines such as TNF‑α, IL‑17, and IL‑23 while enhancing anti‑inflammatory mediators, leading to reduced inflammation in skin and joints.

The dosing regimen for Otezla is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Typically, treatment starts with a titration schedule to reach the maintenance dose, but the exact amount and schedule must be individualized by a qualified healthcare professional.

Safety data for apremilast in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Otezla. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Otezla is an oral small‑molecule therapy, whereas many alternatives such as biologics are injectable monoclonal antibodies. Compared with biologics, apremilast offers a convenient oral route and a different safety profile, lacking immunosuppression but potentially causing gastrointestinal upset and mood changes. Choice depends on disease severity, patient preference, and comorbidities.

Otezla tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Otezla is taken orally, usually once daily with or without food, following a titration schedule to minimize gastrointestinal side effects. Patients should swallow the tablet whole with water and avoid crushing or chewing it.

The most serious risks include the potential for depression, suicidal thoughts, severe allergic reactions, and rare cases of pancreatitis. Patients should be monitored for mood changes, signs of infection, and any unexplained abdominal pain, and should seek immediate medical attention if serious symptoms develop.

Otezla is contraindicated in individuals with known hypersensitivity to apremilast or any of its excipients. It should also be avoided in patients with severe hepatic impairment and used with caution in those with moderate renal dysfunction, uncontrolled depression, or active serious infections.